Zelisse Hein S, van Gent Mignon D J M, Mom Constantijne H, de Ridder Sander, Snijders Malou L H, Heeling Marlou, Stoter Matthijs, Broeks Annegien, Horlings Hugo M, Lok Christianne A R, Bosch Steven L, Piek Jurgen M, Bart Joost, Reyners Anna K L, Wisman G Bea A, Yigit Refika, Boere Ingrid A, Collée Margriet, Groenendijk Floris H, Jansen Maurice P H M, Roes Eva-Maria, Hofhuis Ward, Hoogduin Klaas J, Alcalá Luthy S M, Smedts Huberdina P M, Makkus Alexander C F, Nieuwenhuyzen-de Boer Gatske M, van Es Nicole, Vencken Peggy M L H, van Altena Anne M, Simons Michiel, Hazelbag Hans Marten, Kagie Marjolein J, Aliredjo Riena, Bonestroo Tijmen J J, Bosse Tjalling, de Kroon Cor D, Brinkhuis Mariël, Janssen Marc-Jan, Koster Nils C, Kruse Arnold-Jan, Gerestein Cornelis G, Jonges Trudy G N, Zweemer Ronald P, Kooreman Loes F S, Lambrechts Sandrina, Ebisch Inge M W, de Kievit van der Heijden Ineke M, Voorham Quirinus J, van der Aa Maaike A, Belien Jeroen A M, van de Vijver Marc J, Dijk Frederike
Department of Pathology, Cancer Center Amsterdam, Amsterdam Reproduction & Development research institute, Amsterdam UMC, University of Amsterdam, Amsterdam, the Netherlands.
Department of Gynaecologic Oncology, Centre for Gynaecologic Oncology Amsterdam, Cancer Center Amsterdam, Amsterdam UMC, University of Amsterdam, Amsterdam, the Netherlands.
Ann Diagn Pathol. 2025 Feb;74:152411. doi: 10.1016/j.anndiagpath.2024.152411. Epub 2024 Nov 19.
Fundamental and translational research in ovarian cancer aims to enhance understanding of disease mechanisms and improve treatment and survival outcomes. To support this, we established the Dutch multicenter, interdisciplinary Archipelago of Ovarian Cancer Research (AOCR) infrastructure, which includes a nationwide biobank. In this study, we share our experiences in establishing the infrastructure, offer guidance for similar initiatives, and evaluate the AOCR patient cohort. Key challenges included obtaining Data Protection Impact Assessment (DPIA) clearance, drafting the consortium agreement, and securing ethical approval from all hospitals. Over three years, 1093 patients were enrolled across 17 hospitals, resulting in the collection of 1339 tissue samples and 2280 blood samples. Of the 523 patients with currently available clinical and pathological data, 74 % (n = 387) had primary ovarian cancer. Among these patients, 73.4 % was diagnosed with high-grade serous ovarian carcinoma, and 80.9 % presented with advanced-stage disease. Surgery was performed on 93 % of patients with primary ovarian cancer, and chemotherapy was administered to 90.4 % of these patients. In conclusion, the AOCR biobank has established a robust foundation for future fundamental and translational ovarian cancer research. This manuscript provides valuable insights and guidance for developing future research infrastructures and biobanks, and contains detailed information about the AOCR patient cohort to date.
卵巢癌的基础研究和转化研究旨在增进对疾病机制的理解，改善治疗效果和生存结局。为支持这一目标，我们建立了荷兰多中心、跨学科的卵巢癌研究群岛（AOCR）基础设施，其中包括一个全国性生物样本库。在本研究中，我们分享建立该基础设施的经验，为类似项目提供指导，并评估AOCR患者队列。主要挑战包括获得数据保护影响评估（DPIA）批准、起草联盟协议以及获得所有医院的伦理批准。在三年多的时间里，17家医院共招募了1093名患者，收集了1339份组织样本和2280份血液样本。在523名目前有临床和病理数据的患者中，74%（n = 387）患有原发性卵巢癌。在这些患者中，73.4%被诊断为高级别浆液性卵巢癌，80.9%为晚期疾病。93%的原发性卵巢癌患者接受了手术，其中90.4%的患者接受了化疗。总之，AOCR生物样本库为未来卵巢癌的基础研究和转化研究奠定了坚实的基础。本手稿为未来研究基础设施和生物样本库的发展提供了有价值的见解和指导，并包含了迄今为止AOCR患者队列的详细信息。
Zotero 插件